California Pharmacist vol. 72, no. 3 FALL 2025 - Flipbook - Page 23
Table 2. Key Cardiovascular Outcomes from Clinical Trials of GLP-1 RAs and Tirzepatide
Agents
Weekly semaglutide
0.5–1.0 mg
Trials
SUSTAIN 6 (2016)6
Daily oral semaglutide
14 mg
PIONEER 6 (2019)10
Weekly semaglutide 2.4
mg
SELECT (2023)7
Daily oral semaglutide
14 mg
SOUL (2025)11
Weekly dulaglutide 1.5
mg
REWIND (2019)12
Daily SC liraglutide 1.8
mg
LEADER (2016)13
Daily SC liraglutide 1.8
mg
FIGHT (2016)18
Daily SC liraglutide 1.8
mg
Weekly SC tirzepatide
2.5–15mg
STARDUST (2024)14
SUMMIT (2024)17
Results
CV death:
0.9% vs 1.9% (HR 0.49; CI: 0.27–0.92)
Nonfatal MI:
2.9% vs 3.9% (HR 0.74; CI: 0.51–1.08)
Nonfatal stroke:
0.8% vs 1.0% (HR 0.74; CI: 0.35–1.57)
CV death:
3.8% vs 4.8% (HR 0.79; CI: 0.57–1.11)
Nonfatal MI:
2.3% vs 1.9% (HR 1.18; CI: 0.73–1.90)
Nonfatal stroke:
0.8% vs 1.0% (HR 0.74; CI: 0.35–1.57)
CV death:
6.5% vs 8.0% (HR 0.80; CI, 0.72–0.90)
Nonfatal MI:
2.7% vs 3.7% (HR 0.72; CI: 0.61–0.85)
Nonfatal stroke:
1.7% vs 1.9% (HR 0.93; CI: 0.74–1.15)
CV death:
12% vs 13.8% (HR 0.86; CI: 0.77–0.96)
Nonfatal MI:
4.0% vs 5.2% (HR 0.74; CI: 0.61–0.89)
Nonfatal stroke:
3.0% vs 3.3% (HR 0.88; CI: 0.70–1.11)
CV death:
6.4% vs 7.0% (HR 0.91; CI: 0.78–1.06)
Nonfatal MI:
4.1% vs 4.3% (HR 0·96; CI: 0·79–1·16)
Nonfatal stroke:
2.7% vs 3.5% (HR 0.76; CI: 0.61-0.95)
CV Death:
4.7% vs 6.0% (HR 0.78; CI: 0.66–0.93)
Nonfatal MI:
6.0% vs 6.8% (HR 0.88; CI: 0.75–1.03)
Nonfatal stroke:
3.4% vs 3.8% (HR 0.89; CI: 0.72–1.11)
Time to death:
12% vs 11% (HR 1.10; CI: 0.57–2.14)
HF rehospitalization:
41% vs 34% (HR 1.30; CI: 0.89–1.88)
TcPo2 from baseline:
+11.2 mm Hg (CI: 8.0–14.5)
Adjudicated death from CV causes or a
worsening HF event:
9.9% vs 15.3% (HR 0.62; CI: 0.41–0.95)
Change in KCCQ-CSS:
+6.9 points (CI: 3.3–10.6)
Change in body weight:
–13.9% (CI: –12.9 to –10.4)
Sample Sizes (n)
3,927
3,183
17,604
9,650
9,901
9,340
300
89
731
Continued on next page
California Pharmacist | vol. 72, no. 3
21
